高危前列腺癌根治术后辅助雄激素剥夺联合或不联合米托蒽醌+泼尼松的III期试验:SWOG S9921
中位随访11.2年,10年OS在ADT组为87%、ADT+MP组为86%(HR 1.06,95%CI 0.79-1.43),两组DFS均为72%。MP未改善OS且增加其他恶性肿瘤死亡,试验因MP组白血病发生率更高提前停止入组。
要点
- 在高危前列腺癌根治术后患者中,辅助ADT联合MP对比单纯ADT未改善总生存。
- MP组其他恶性肿瘤死亡比例更高(36% vs 18%),且白血病发生率增加导致提前终止入组。
- 单纯2年辅助ADT的10年OS达87%,优于历史预估的50%,但缺乏无治疗对照组。
核心结论
- 在根治术后高危前列腺癌患者中,辅助ADT联合MP对比单纯ADT未改善OS,且增加其他恶性肿瘤死亡。
- 单纯2年辅助ADT的DFS和10年OS优于历史估计,但因无无治疗对照臂,无法对ADT的价值做出确定性结论。
研究设计与样本
- eligible患者为根治术后cT1-3N0前列腺癌且具备至少一项高危因素(GS≥8;pT3b、pT4或pN+;GS 7且切缘阳性;或术前PSA>15 ng/mL、活检GS>7、或PSA>10 ng/mL且活检GS>6),术后PSA≤0.2 ng/mL。
- 按pT/N分期、GS和辅助放疗计划分层,随机分配至ADT组(比卡鲁胺+戈舍瑞林2年)或ADT+MP组(联合6周期米托蒽醌+泼尼松)。
主要发现
- 中位随访11.2年,ADT组10年OS估计为87%(预期50%),ADT+MP组为86%(HR 1.06;95%CI 0.79-1.43)。
- 两组10年无病生存(DFS)估计均为72%。
- ADT组18%患者死于前列腺癌,ADT+MP组为22%。
- ADT+MP组更多患者死于其他恶性肿瘤(36% vs ADT单药组18%)。
- 因ADT+MP组白血病发生率更高,数据安全监测委员会建议停止入组。
临床怎么用
- 不推荐在高危前列腺癌根治术后辅助ADT基础上联合米托蒽醌+泼尼松,因无OS获益且增加其他恶性肿瘤死亡。
- 2年辅助ADT方案(比卡鲁胺+戈舍瑞林)在本试验中显示出优于历史估计的10年OS和DFS,但需注意缺乏无治疗对照。
局限性
- 试验因ADT+MP组白血病发生率更高提前停止入组,可能影响统计效能。
- 无无治疗对照臂,无法确定ADT本身的绝对获益。
- 历史预期OS(50%)与实际观察(87%)差异较大,可能反映人群选择或分期偏移。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Purpose Patients with high-risk prostate cancer after radical prostatectomy are at risk for death. Adjuvant androgen-deprivation therapy (ADT) may reduce this risk. We hypothesized that the addition of mitoxantrone and prednisone (MP) to adjuvant ADT could reduce mortality compared with adjuvant ADT alone. Methods Eligible patients had cT1-3N0 prostate cancer with one or more high-risk factors after radical prostatectomy (Gleason score [GS] ≥ 8; pT3b, pT4, or pN+ disease; GS 7 and positive margins; or preoperative prostate-specific antigen [PSA] > 15 ng/mL, biopsy GS score > 7, or PSA > 10 ng/mL plus biopsy GS > 6. Patients with PSA ≤ 0.2 ng/mL after radical prostatectomy were stratified by pT/N stage, GS, and adjuvant radiation plan and randomly assigned to ADT (bicalutamide and goserelin for 2 years) or ADT plus six cycles of MP. The primary end point was overall survival (OS). Median OS was projected to be 10 years in the ADT arm, requiring 680 patients per arm to detect a hazard ratio of 1.30 with 92% power and one-sided α = .05. Results Nine hundred sixty-one eligible intent-to-treat patients were randomly assigned to ADT or ADT + MP from October 1999 to January 2007, when the Data Safety Monitoring Committee recommended stopping accrual as a result of higher leukemia incidence with ADT + MP. Median follow-up was 11.2 years. The 10-year OS estimates were 87% with ADT (expected 50%) and 86% with ADT + MP (hazard ratio, 1.06; 95% CI, 0.79 to 1.43). The 10-year estimate for disease-free survival was 72% for both arms. Prostate cancer was the cause of death in 18% of patients in the ADT arm and 22% in the ADT + MP arm. More patients in the MP arm died of other cancers (36% v 18% in ADT alone arm). Conclusion MP did not improve OS and increased deaths from other malignancies. The DFS and 10-year OS in these patients treated with 2 years of ADT were encouraging compared with historical estimates, although a definitive conclusion regarding value of ADT may not be made without a nontreatment control arm.
引用
- Hussain M, Tangen CM, Thompson IM, et al. Phase III Intergroup Trial of Adjuvant Androgen Deprivation With or Without Mitoxantrone Plus Prednisone in Patients With High-Risk Prostate Cancer After Radical Prostatectomy: SWOG S9921. J Clin Oncol. 2018. PMID: 29624463. doi:10.1200/JCO.2017.76.4126
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。